Literature DB >> 2672247

Use of quinolones for the treatment of patients with bacteremia.

P M Shah1.   

Abstract

Quinolones have been shown in vitro to be highly active against Enterobacteriaceae and Pseudomonas aeruginosa and moderately active against some of the gram-positive cocci. Quinolones have been administered both orally and intravenously to treat patients with bacteremia due in large part to Enterobacteriaceae. The largest experience so far has been in the treatment of Salmonella bacteremia followed by bacteremia caused by Escherichia coli. Quinolones have been shown to be active and well tolerated in the treatment of patients with serious and bacteremic infections and a variety of underlying conditions. However, the clinical experience thus far is limited.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2672247     DOI: 10.1093/clinids/11.supplement_5.s1156

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  5 in total

Review 1.  Use of quinolones in the immunocompromised host.

Authors:  A G Maiche
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

2.  Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field.

Authors:  E Giraud; A Brisabois; J L Martel; E Chaslus-Dancla
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

3.  Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolated from humans and animals.

Authors:  D J Griggs; K Gensberg; L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

4.  Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations.

Authors:  A G Maiche; L Teerenhovi
Journal:  Infection       Date:  1991       Impact factor: 3.553

5.  Prophylaxis with ofloxacin in patients with cancer and neutropenia.

Authors:  A G Maiche
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.